Metrics as of 10/15/2026, 10:05 PM (Berlin time), refresh in progress.
Cogent Biosciences Stock
Cogent Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Andrew R. Robbins
- Employees
- 258
- Market cap
- $5.1 B
- IPO
- 29/03/2018
Cogent Biosciences, Inc. is a healthcare company based in Waltham, US, dedicated to the development of targeted treatments for illnesses rooted in specific genetic anomalies. Founded in 2014, the company previously operated under the name Unum Therapeutics Inc. before adopting its current name in October 2020. With…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Cogent Biosciences stock: price history
1D
+4.8%
1W
-1.9%
1M
-9.9%
6M
-18.5%
YTD
-16.9%
1Y
+78.0%
2Y
+152.8%
5Y
+219.3%
10Y
–
Next earnings date
Next earnings date
06/11/2026 (in 20 days)
Volatility around earnings
~26% stronger price swings than usual
Ask the agents about Cogent Biosciences
Analyst assessment of Cogent Biosciences
PRICE TARGET LOW
US$45.00
CONSENSUS
US$51.75
MEDIAN
US$53.50
PRICE TARGET HIGH
US$55.00
0
STRONG BUY
10
BUY
2
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 16/09/2026
Cogent Biosciences stock metrics
P/E
-12.77
P/B
9.48
EV/EBITDA
-13.92
RETURN ON EQUITY
-18.1%
NET MARGIN
0.0%
DEBT/EQUITY
0.46
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
89.8%
FLOAT SHARES
155,830,656
AVG. DAILY VOLUME (30D)
2,144,651
Insider transactions (SEC)
Morris Arlene
Morris Arlene
Morris Arlene
Morris Arlene
Robbins Andrew R
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Cogent Biosciences stock
What does Cogent Biosciences do?
Cogent Biosciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Andrew R. Robbins, the company employs around 258 people.
The IPO was on 29/03/2018; the stock trades on NASDAQ under the ticker COGT.
What do analysts say about Cogent Biosciences stock?
12 analysts rate the stock, the consensus is Buy (as of 16/09/2026).
The average price target is US$51.75, ranging from US$45.00 to US$55.00, with a median of US$53.50.
This is an external assessment, not a statement by Market Jury.
When does Cogent Biosciences report next?
The next earnings date is 06/11/2026.
Around past earnings, price swings were roughly 26% stronger than usual.
Does Cogent Biosciences pay a dividend?
No, Cogent Biosciences currently does not pay a dividend.
Which stocks are comparable to Cogent Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Cogent Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Cogent Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.